Key Takeaways
- Shares of Capricor Therapeutics (CAPR) surged following the presentation of extended Phase 3 trial results for deramiocel at the World Muscle Society congress in Hiroshima.
- Extended trial data revealed 82 out of 106 HOPE-3 participants completed the 24-month evaluation period, with findings now integrated into the FDA submission.
- The therapy successfully achieved its primary 12-month endpoint, demonstrating a 54% reduction in upper-limb function decline compared to placebo.
- Despite a July FDA advisory panel voting 9-3 against approval for cardiomyopathy indication, panelists expressed greater optimism regarding upper-limb efficacy data.
- The FDA’s final verdict is scheduled for November 22 under the PDUFA target date.
Capricor Therapeutics stock gained ground during after-hours trading Tuesday following the biotech’s disclosure of extended clinical trial findings for deramiocel, an investigational therapy targeting Duchenne muscular dystrophy. The information emerged through ePosters presented at the World Muscle Society’s 31st Annual Congress taking place in Hiroshima, Japan.
Capricor Therapeutics, Inc., CAPR
The disclosure’s timing carries significant weight. With an FDA regulatory determination scheduled for November 22, Capricor isn’t simply sharing conference updates. The extended data forms part of a substantial amendment submitted to the company’s Biologics License Application, ensuring regulators have access to these findings during their review process.
The presented poster encompasses participants from both the Phase 3 HOPE-3 study and its subsequent open-label extension phase. From an initial cohort of 106 randomized participants, 82 completed the full 24-month evaluation period. This subset consisted of 40 individuals who received deramiocel from trial initiation and 42 who initially received placebo.
Understanding the Delayed-Start Trial Architecture
The study employed a delayed-start framework. During the initial 12-month period, participants received either deramiocel or placebo. Subsequently, eligible participants could transition into the open-label extension phase and begin deramiocel treatment irrespective of their original randomization group.
This design enables investigators to assess differences between immediate treatment versus delayed initiation. It addresses whether early intervention confers sustained advantages and whether placebo-group patients demonstrate trajectory changes following crossover. The poster additionally compares two-year outcomes against natural history datasets, providing context for typical disease progression patterns.
These extended findings expand upon the initial 12-month HOPE-3 outcomes. The original trial successfully achieved its primary endpoint, demonstrating a 54% reduction in upper-limb function deterioration versus placebo as measured by the Performance of the Upper Limb 2.0 assessment. The statistical significance registered at p=0.03. The Lancet published these initial findings in July.
Navigating FDA’s Preliminary Feedback
The approval pathway has encountered obstacles. A July FDA advisory committee determined by a 9-3 margin that available evidence didn’t adequately demonstrate deramiocel’s efficacy specifically for cardiomyopathy treatment in Duchenne patients.
That particular vote had limited scope. It exclusively evaluated the cardiomyopathy indication rather than assessing the drug’s comprehensive risk-benefit profile, and committee members expressed more encouraging perspectives when discussing HOPE-3 upper-limb efficacy data. Additionally, the FDA maintains discretion to approve or reject regardless of advisory committee recommendations.
Capricor is leveraging the WMS congress to present earlier-stage research initiatives. A poster scheduled for Wednesday presentation describes the company’s StealthX exosome technology platform, designed to deliver micro-dystrophin as a redosable therapeutic approach for Duchenne. An additional Friday poster covers a comparable delivery mechanism targeting Pompe disease.
Both initiatives remain in preclinical development stages, indicating they’re several years from potential regulatory review. They provide stakeholders visibility into Capricor’s development portfolio beyond the lead deramiocel candidate.
Additional congress activities are planned throughout the week. UC Davis’s Craig McDonald is scheduled to deliver an oral presentation on October 3 examining HOPE-3 evidence addressing both skeletal muscle and cardiac outcomes.
Capricor has indicated it will publish presentation materials and posters on its corporate website following each session’s conclusion. The company currently maintains a market capitalization near $498 million and doesn’t yet generate commercial product revenue, instead depending on financing activities and strategic partnerships including its Japanese collaboration with Nippon Shinyaku.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
